We’re pleased to announce the appointment of Marc Rees in the role of Business Development Manager responsible for UK and Ireland.
Marc brings an extensive background in clinical and pharmaceutical development services, having worked for more than 20 years in relevant business development roles for leading contract development organizations and pharmaceutical services providers. Marc has experience working within the technical roles in pharmaceuticals as well as business development, demonstrating an excellent well-rounded knowledge of the sector.
Marc will be responsible for account management and territory growth in the UK and Ireland for the company’s international clinical packaging and logistics services, maintaining and growing market share with key customers while developing new business, as well as identifying opportunities for PCI’s high potency oral solid manufacturing, commercial packaging and analytical testing services.
Paul Viggers, Clinical Business Development Director, stated: “We are excited for the breadth of experience Marc is adding to our current team. He brings with him a proven track record in supporting clients across the clinical and pharmaceutical sector. His background will be invaluable in helping our clients realize successful clinical trials and shepherding to commercialization.”
Marc stated: “It is great to be working alongside the amazing team at PCI. I have always worked in the sector so I have great background to leverage for the benefit of our clients. I am looking forward to getting into my new role and utilizing my experiences and insights to deliver the industry’s leading experience to both new and current clients.”
We have announced considerable investment in its clinical trials business over the past year, including the expansion of our Cold Chain infrastructure at its North American clinical logistics facility in Rockford, IL. The additional expansion of on-site cryogenic storage complements our extensive refrigerated and frozen on-site storage. In addition, we have announced a significant site expansion of our Bridgend, Wales, UK clinical centre of excellence. Our Bridgend site specialises in a broad range of temperature controlled packaging, storage and distribution capabilities.
These developments follow our announcement of the site expansion for our drug development and clinical trial manufacturing center of excellence in Tredegar, Wales, UK, including the purchase of a fully contained Xcelodose 600 unit for contained development of potent compounds in early phase clinical study.